Health Care/Hospital
Tsingke Shines at Cell & Gene Therapy International 2024
BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...
2024-10-14 20:11
1418
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute
TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...
2024-10-14 19:00
1630
Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...
2024-10-14 19:00
1551
Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices inChina, which recently expanded into the U.S. market following its U.S. FDA 510(k) clea...
2024-10-14 17:00
917
BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN)
SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place fromOctober 23 to 27 in San Di...
2024-10-14 15:38
1481
Embark on a Journey of Holistic Wellbeing at Banyan Tree Dubai's Brand-New Spa
Offering seven private ensuite treatment rooms featuring jacuzzis and showers, the spa provides the ideal retreat to unwind, complemented by vitality pools, heated loungers, and the signature Rainforest experience DUBAI, UAE, Oct. 14, 2024 /PRNewswire/ -- Relaxation takes on a renewed essence at...
2024-10-14 13:00
2266
Novotech Awarded Frost & Sullivan's 2024 Global Company of the Year Award for Its Leadership and Excellence in Biotech CRO Services
Novotech's innovative full-service approach accelerates clinical development with advanced analytics, diverse global patient access, and specialized technology. SAN ANTONIO, Oct. 14, 2024 /PRNewswire/ -- Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research or...
2024-10-14 12:30
1123
21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain
TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled forSaturday, October 19, 2024, at the Hyatt Regency Hotel inSanta Clara, California, will focus on the theme "Taiwan's Strategic Layout in the AI Era." The conference will explore howTaiwan leverages its...
2024-10-14 10:32
1202
Zhejiang Taimei Medical Technology Co., Ltd. Is Now Listed on HKEX
HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Zhejiang Taimei Medical Technology Co., Ltd. (the "Company"; Stock code: 2576.HK) has announced that the shares have started to be traded on the Main Board of the Stock Exchange of Hong Kong Limited under the stock code "2576" since today. The Company sai...
2024-10-14 10:18
1196
Modern Meadow Appoints David Williamson as CEO
With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...
2024-10-14 09:00
1276
Modern Meadow Appoints David Williamson as CEO
With his extensive background in material science, biotechnology and production environments,Williamson set to lead company as CEO starting October 14 Modern Meadow continues to build its BIO-VERA® brand and expand production NUTLEY, N.J., Oct. 14, 2024 /PRNewswire/ -- Modern Meadow, a leader in...
2024-10-14 09:00
1030
Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis
News Summary: * Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders. * Novel digestion enzymes deliver complete RNA sequenc...
2024-10-14 08:00
1532
UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes
VIENNA, Oct. 14, 2024 /PRNewswire/ -- Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy. This innovative approach, which combines a novel pro...
2024-10-14 06:01
1313
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately$250 million US...
2024-10-13 20:27
3355
Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...
2024-10-13 16:04
2035
90th CMEF in Shenzhen Showcases Global MedTech Innovations and Insights
SHENZHEN, China, Oct. 13, 2024 /PRNewswire/ -- The 90th China International Medical Equipment Fair (CMEF) has successfully kicked off inShenzhen, running fromOctober 12-15. This year's event spans nearly 200,000 square meters and hosts nearly 4,000 exhibitors with an audience surpassing 200,000 f...
2024-10-13 15:54
4568
World Thrombosis Day raises global awareness of blood clot dangers through actionable initiatives
Help shape the future of women's health by taking the survey and supporting this global campaign in its eleventh year to improve care for at-risk patients. CHAPEL HILL, N.C., Oct. 13, 2024 /PRNewswire/ -- Today is World Thrombosis Day , a global campaign established by theInternational Society on ...
2024-10-13 14:00
1317
Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...
2024-10-12 16:57
4022
X3 Holdings Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Requirement
SINGAPORE, Oct. 11, 2024 /PRNewswire/ -- X3 Holdings Co., Ltd. (Nasdaq: XTKG) (the "Company" or "XTKG"), a global provider of digital solutions and technology services spanning diverse industries, today announced that it has received an extension of 180 calendar days from the Listing Qualificatio...
2024-10-12 04:30
5292
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...
2024-10-11 20:00
4386
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
